Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 | P35372 | 9/20 | 0.32 |
| ▸ | OPRK1 | P41145 | 9/20 | 0.32 |
| ▸ | ITGB3 | P05106 | 3/20 | 0.31 |
| ▸ | ITGA2B | P08514 | 3/20 | 0.31 |
| ▸ | ACE | P12821 | 1/20 | 0.31 |
| ▸ | DPP4 | P27487 | 1/20 | 0.31 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.31 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.31 |
| ▸ | NTMT1 | Q9BV86 | 1/20 | 0.30 |
| ▸ | F2 | P00734 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25476870 | 0.96 | F2 (0.32) | DPP4F2 | |
| SCHEMBL21168338 | 0.93 | ACE (0.36) | ACEF2 | |
| SCHEMBL21168372 | 0.93 | ACE (0.36) | ACEF2 | |
| SCHEMBL25476844 | 0.91 | BMP1 (0.33) | DPP4F2 | |
| SCHEMBL25476845 | 0.91 | VSIR (0.31) | DPP4F2 | |
| SCHEMBL25476841 | 0.91 | F2 (0.33) | ACEDPP4F2 | |
| SCHEMBL25476843 | 0.91 | ACE (0.32) | ACEDPP4F2 | |
| SCHEMBL25476867 | 0.91 | VSIR (0.35) | F2 | |
| SCHEMBL25476866 | 0.90 | VSIR (0.33) | ITGB3ITGA2BF2 | |
| SCHEMBL23351265 | 0.89 | FABP4 (0.32) | ACEDPP4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230144653-A1 | 1,2,4-Oxadiazole Compounds as Inhibitors of CD47 Signalling Pathways | AURIGENE ONCOLOGY LIMITED (IN) | 2023-05-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230144653-A1 | 1,2,4-Oxadiazole Compounds as Inhibitors of CD47 Signalling Pathways | CD47, HIF1AN, PIK3R5 | OPRM1 4595/4885OPRK1 4413/4885ITGB3 241/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.